Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration-Reference-Cited by-同舟云学术

Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration

Published:2022-12-27 Issue:2 Volume:91 Page:143-156
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Guo Fei^ORCID,Liu Bingyan,Li Xiaoli,Wang Haidong,Zhu Xingyu,Su Yue,He Cuixia,Zhu Minhui,Ding Jiaxiang,Xu Yuanyuan,Zhao Xiangdi,Wang Ying,Shan Rongfang,Zhu Juan,Xie Jing,Ge Qin,Fan Ling,Ding Yuzhou,Xie Yunqiu,Zhang Chaoyang,Li Hongtao,Wang Hongju,Zhou Huan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-022-04493-5.pdf

Reference24 articles.

1. Shanbhag S, Ambinder RF (2018) Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin 68(2):116–132. https://doi.org/10.3322/caac.21438

2. Miranda-Filho A, Piñeros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F (2019) Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control 30(5):489–499. https://doi.org/10.1007/s10552-019-01155-5

3. Cao W, Chen HD, Yu YW, Li N, Chen WQ (2021) Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 134(7):783–791. https://doi.org/10.1097/cm9.0000000000001474

4. Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, Sabichi AL, Ao X, Maeng H, Samaniego F (2013) Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood 121(23):4729–4739. https://doi.org/10.1182/blood-2012-12-471094

5. Au KM, Balhorn R, Balhorn MC, Park SI, Wang AZ (2019) High-performance concurrent chemo-immuno-radiotherapy for the treatment of hematologic cancer through selective high-affinity ligand antibody mimic-functionalized doxorubicin-encapsulated nanoparticles. ACS Cent Sci 5(1):122–144. https://doi.org/10.1021/acscentsci.8b00746